Estimation of the Possible Economic Effects of Pre-Endoscopic Screening with F-calprotectin, Clinical Biochemistry

BÜHLMANN fCAL® ELISA Citation:

Mindemark, M. & Larsson, A.  Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry.  Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015.

Highlights from this Publication

“The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up to €2.13 million.”

Read Citation

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use.

Health Canada License: 80726